Jae Won Chang1, Ki Wan Park1, Jae Hyung Heo1, Seung-Nam Jung1, Lihua Liu2, Sung Min Kim3, In Sun Kwon4, Bon Seok Koo5. 1. Department of Otolaryngology-Head and Neck Surgery, Research Institute for Medical Science, College of Medicine, Chungnam National University, 640 Daesa-Dong, Chung-Gu, Daejeon, 301-721, Republic of Korea. 2. Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. 3. Department of Nuclear Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. 4. Clinical Trial Center, Chungnam National University Hospital, Daejeon, Republic of Korea. 5. Department of Otolaryngology-Head and Neck Surgery, Research Institute for Medical Science, College of Medicine, Chungnam National University, 640 Daesa-Dong, Chung-Gu, Daejeon, 301-721, Republic of Korea. bskoo515@cnuh.co.kr.
Abstract
BACKGROUND: To determine whether 18F-fluoro-2-deoxyglucose (18F-FDG)-PET/CT is useful for predicting the BRAF V600E mutation status of a primary papillary thyroid carcinoma (PTC). METHODS: A retrospective analysis was performed in 108 patients who underwent 18F-FDG positron emission tomography-computed tomography (PET/CT) for staging before thyroidectomy and BRAF analysis in biopsy-confirmed PTC. The maximum standardized uptake value (SUVmax) of the primary tumor was calculated according to FDG accumulation. Univariate and multivariate analyses were performed to assess the association between the SUVmax and clinicopathological variables. RESULTS: The BRAF V600E mutation was detected in 71 of 108 (65.7%) patients. In all subjects, the tumor size and BRAF V600E mutation were independently related to the SUVmax according to multivariate analyses (P = 0.002 and 0.007, respectively). The SUVmax was significantly higher in tumors with the BRAF V600E mutation than in tumors with wild-type BRAF (10.24 ± 11.89 versus 4.02 ± 3.86; P = 0.007). In the tumor size >1 cm subgroup, the BRAF V600E mutation was the only factor significantly associated with the SUVmax (P = 0.016). A SUVmax cutoff level of 4.9 was determined to be significant for predicting the BRAF V600E mutation status (sensitivity 77.4%, specificity 100.0%, area under the curve 0.929; P < 0.0001) according to ROC curve analysis. CONCLUSIONS: The BRAF V600E mutation is independently associated with high 18F-FDG uptake in PTC, especially in those with a tumor size >1 cm.
BACKGROUND: To determine whether 18F-fluoro-2-deoxyglucose (18F-FDG)-PET/CT is useful for predicting the BRAFV600E mutation status of a primary papillary thyroid carcinoma (PTC). METHODS: A retrospective analysis was performed in 108 patients who underwent 18F-FDG positron emission tomography-computed tomography (PET/CT) for staging before thyroidectomy and BRAF analysis in biopsy-confirmed PTC. The maximum standardized uptake value (SUVmax) of the primary tumor was calculated according to FDG accumulation. Univariate and multivariate analyses were performed to assess the association between the SUVmax and clinicopathological variables. RESULTS: The BRAFV600E mutation was detected in 71 of 108 (65.7%) patients. In all subjects, the tumor size and BRAFV600E mutation were independently related to the SUVmax according to multivariate analyses (P = 0.002 and 0.007, respectively). The SUVmax was significantly higher in tumors with the BRAFV600E mutation than in tumors with wild-type BRAF (10.24 ± 11.89 versus 4.02 ± 3.86; P = 0.007). In the tumor size >1 cm subgroup, the BRAFV600E mutation was the only factor significantly associated with the SUVmax (P = 0.016). A SUVmax cutoff level of 4.9 was determined to be significant for predicting the BRAFV600E mutation status (sensitivity 77.4%, specificity 100.0%, area under the curve 0.929; P < 0.0001) according to ROC curve analysis. CONCLUSIONS: The BRAFV600E mutation is independently associated with high 18F-FDG uptake in PTC, especially in those with a tumor size >1 cm.
Authors: Salvatore Vaccarella; Silvia Franceschi; Freddie Bray; Christopher P Wild; Martyn Plummer; Luigino Dal Maso Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Suk Hyun Lee; Sangwon Han; Hyo Sang Lee; Sun Young Chae; Jong Jin Lee; Dong Eun Song; Jin-Sook Ryu Journal: Nucl Med Mol Imaging Date: 2015-09-22
Authors: Le Ngoc Ha; Amir Iravani; Nguyen Thi Nhung; Ngo Thi Minh Hanh; Febby Hutomo; Mai Hong Son Journal: Cancer Imaging Date: 2021-01-07 Impact factor: 3.909